News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SASY.PA) Signs Crohn's Disease Pact With Glenmark Pharmaceuticals; Deal Expected to be Worth $613 Million



5/16/2011 7:21:34 AM

Indian drugmaker Glenmark Pharmaceuticals said on Monday its unit has signed a licensing agreement with France's Sanofi to develop and commercialise a novel monoclonal antibody, sending its shares up nearly 20 percent. Under the terms of the agreement, Glenmark is expected to receive as much as $613 million, in addition to double-digit royalties on sales of products commercialised under the license. The molecule, GBR500, is used for the treatment of Crohn's disease and other inflammatory conditions.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES